Vietnam Vaccine JSC (VNVC) and GSK Vietnam have strengthened their strategic partnership to accelerate access to new medicines and vaccines, advance scientific research, and collaborate in vaccine manufacturing.
The agreement, formalized on Oct. 30 in the U.K. as witnessed by Party General Secretary To Lam and Matt Western, the U.K. Government's Trade Envoy, seeks to bring advanced specialty medicines produced at GSK's global manufacturing hubs in Worthing and Barnard Castle to Vietnam.
The MOU is expected to unlock cooperation opportunities valued at £500 million (approximately US$578 million, VND17 trillion) over five years, while supporting Vietnam's goals for domestic vaccine production and biopharmaceutical innovation.
 |
Party General Secretary To Lam (5th L, second row) and Matt Western (4th L, second row), the U.K. Government's Trade Envoy witnessed the handover of cooperation documents between Ngo Chi Dung (R, front row), Chairman and General Director of Vietnam Vaccine JSC (VNVC), and Kaja Natland, Senior Vice President of GSK Asia–Pacific & International. Photo courtesy of HTN |
Speaking at the Vietnam–U.K. High-Level Economic Conference, General Secretary To Lam highlighted three priority areas for future cooperation: joint R&D in transformative technologies such as AI and healthcare; talent exchange and digital-transformation initiatives; and greater private-sector collaboration in technology and health innovation.
The General Secretary emphasized Vietnam's readiness to serve as a reliable partner in global science and innovation, benefiting citizens of both countries and contributing to regional development.
 |
Ngo Chi Dung (R), Chairman and General Director of Vietnam Vaccine JSC (VNVC), and Kaja Natland, Senior Vice President of GSK Asia–Pacific & International, at the partnership agreement ceremony. Photo courtesy of Ha Ngan |
Ngo Chi Dung, Chairman and General Director of VNVC, said the expanded partnership builds on six years of collaboration that helped bring next-generation vaccines to Vietnam and address shortages beyond the national immunization program.
Over the past five years, VNVC and the Tam Anh healthcare system have worked with GSK on initiatives valued at nearly £400 million (nearly VND 14 trillion), spanning commercial cooperation, clinical training, and vaccine distribution.
"We are advancing toward early access to breakthrough medicines, from antibiotics to oncology therapies, while strengthening knowledge transfer to support Vietnam's vaccine self-sufficiency," Dung said.
 |
Artist's impression of the VNVC Vaccine and Biological Manufacturing Plant, which is expected to commence operations by the end of 2027. Graphic courtesy of VNVC |
Kaja Natland, Senior Vice President of GSK Asia-Pacific & International, said Vietnam is one of GSK's most important markets in the region, particularly in vaccines and respiratory-infection prevention.
"With our strong partnership foundation, we aim to positively impact the health of more than one-third of Vietnam's population within the next five years," Natland noted.
 |
The strategic cooperation MOU signing ceremony among VNVC, Tam Anh and GSK. Photo courtesy of VNVC |
VNVC operates nearly 250 vaccination centers nationwide and plays a central role in expanding vaccine access for children and adults. In May 2025, it began building the VNVC Vaccine & Biological Manufacturing Plant in Tay Ninh Province that borders Ho Chi Minh City, featuring a projected annual capacity of 100 million doses and an R&D center focused on advanced platforms, including mRNA.
Set to open in 2027, the facility aims to become a leading regional hub for vaccine development and production, enhancing Vietnam's position in the global vaccine supply chain.
GSK continues to advance its global portfolio of vaccines and specialty medicines across respiratory, immunology, oncology, HIV, and infectious diseases.